Angle PLC Issue of Equity (0830K)
April 14 2015 - 2:00AM
UK Regulatory
TIDMAGL
RNS Number : 0830K
Angle PLC
14 April 2015
For immediate release 14 April 2015
ANGLE plc
("ANGLE" or "the Company")
Issue of Equity
ANGLE plc (AIM:AGL and OTCQX:ANPCY), the specialist medtech
company, announces that it has received notice from an employee to
exercise options over 83,333 ordinary shares of 10p each in the
Company. Share options were issued to employees pursuant to the
arrangements set out in the Company's Share Option Schemes.
Accordingly the Company has allotted 83,333 new ordinary shares
of 10p each ("New Ordinary Shares") in the capital of the Company.
The New Ordinary Shares rank pari passu with the existing ordinary
shares in the Company. An application has been made for the New
Ordinary Shares to be admitted to trading on AIM and admission is
expected to take place at 8.00 am on 17 April 2015. Following this
allotment, the total issued share capital of the Company is
58,974,338 ordinary shares.
For further information:
ANGLE plc 01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys, Dr Christopher
Golden (Nominated adviser)
Russell Kerr, Olly Baxendale
(Sales) 020 7397 8900
Buchanan
Mark Court, Sophie Cowles 020 7466 5000
Notes for editors
About ANGLE plc
ANGLE is a specialist medtech company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology, known as the Parsortix
system, harvests the cells of interest through a liquid biopsy,
with the patient only experiencing a simple blood test. Parsortix
is the subject of two granted US patents and three extensive
families of patents being progressed worldwide. The system is based
on a microfluidic device that captures cells based on a combination
of their size and compressibility. The Parsortix system is
established with strong positive evaluations from leading cancer
research centres and is working with these cancer centres to
demonstrate key applications. Parsortix has a CE Mark for Europe
and FDA authorisation is in process for the US.
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The Parsortix system is designed to be compatible with existing
major medtech analytical platforms and to act as a companion
diagnostic for major pharma in helping to identify patients that
will benefit from a particular drug and then monitoring the drug's
effectiveness.
ANGLE has established formal collaborations with world-class
cancer centres and is working with these cancer centres to
demonstrate key applications for its Parsortix non-invasive cancer
diagnostic system as a liquid biopsy. Details are available here
http://www.angleplc.com/the-company/collaborators/
In addition to cancer, the Parsortix technology has the
potential for deployment with several other important cell types in
the future.
ANGLE began trading on the AIM market of the London Stock
Exchange in March 2004 under the ticker symbol AGL. For more
information visit www.angleplc.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOELLFIDSAIVLIE
Angle (LSE:AGL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Angle (LSE:AGL)
Historical Stock Chart
From Sep 2023 to Sep 2024